+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hormone Replacement Therapy Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5174938
  • Report
  • August 2020
  • Region: Global
  • 115 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2020

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Merck KGaA
  • Mylan NV
  • MORE
Certain factors that are positively affecting the Hormone Replacement Therapy (HRT) market growth are increasing awareness on post-menopausal issues among women, rise in drug development with novel delivery systems, and hormonal imbalance disorders with rising geriatric population.

Hormonal imbalance disorders, with an increase in the geriatric population, is one of the major factors responsible for the growth of the market studied. With various kinds of hormonal changes, the female body predominantly gets affected by the natural process of aging, leading to abnormalities and diseases. Some of the common problems include weight gain, memory decline, fatigue, low libido, aging appearance, and muscle loss.

The most frequently reported consequence of age-related hormonal changes occurs in cases related to menopause. The global average onset age for menopause among women is approximately 50 years. In women, by the age of 50 years and above, the production levels of estrogen and progesterone decrease significantly. The decrease in production levels of estrogen and progesterone are compensated by the pituitary gland, with the increased production of follicle stimulating hormone (FSH). This is physically manifested in women in the form of post-menopause symptoms, which include flush.

These factors associated with age lead to the rising demand for HRT, thus driving the market studied.

Key Market Trends

Application in Menopause Indication is Expected to Growth at High CAGR over Forecast Period

Menopause is the time that marks the end of your menstrual cycles. It's diagnosed after you've gone 12 months without a menstrual period. Menopause can happen in your 40s or 50s. Menopause is a natural biological process. Hormone replacement therapy improves the quality of life and prolongs life for many elderly women, whether it is initiated at menopause or much later. The therapy helps elderly women maintain their estrogen levels.

This application is expected to rise in future as the geriatric population globally is increasing. As per a 2017 report by the United Nations, the percentage of population aged 60 years or above is expected to increase from 12.7% in 2017 to 21.3% by 2050. This change is expected to be more prevalent in developed countries. Hence, as both men and women age, the application of HRT in elderly women is expected to grow, which will help the market growth.

North America Holds the Largest Market Share

Rising geriatric population is one of the primary factors responsible for the growth of the hormonal replacement therapy market in the United States and Canada.

According to the National Institutes of Health (NIH), almost half of all the postmenopausal women in the United States reported having used HRT at least once in their life. The conjugated equine estrogens (CEE)/bazedoxifene tablet, a combination of estrogen and a selective estrogen receptor modulator, is available in the United States for menopausal VMS treatment and osteoporosis prevention.

Overall, the market for HRT in the United States is scheduled for high growth over the forecast period. The major drivers of this market are expected to increase the adoption of HRT among women, for both post-menopausal and menopause management.

Competitive Landscape

The market is consolidated. Several companies with the largest market share are Abbott, Bayer AG, Merck KGaA, Novartis AG, and Pfizer Inc. However, there are efforts being made by new players to enter the hormone replacement therapy market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Merck KGaA
  • Mylan NV
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness on Post-menopausal Issues among Women
4.2.2 Rise in Drug Development with Novel Delivery Systems
4.2.3 Hormonal Imbalance Disorders with Rising Geriatric Population
4.3 Market Restraints
4.3.1 High Cost of Hormone Replacement Therapy
4.3.2 Substantial Risk of Cancer Associated with Hormone Replacement Therapy
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Therapy
5.1.1 Estrogen Hormone Replacement
5.1.2 Growth Hormone Replacement
5.1.3 Thyroid Hormone Replacement
5.1.4 Testosterone Replacement
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Other Routes of Administration
5.3 By Indication
5.3.1 Menopause
5.3.2 Hypothyroidism
5.3.3 Growth Hormone Deficiency
5.3.4 Other Indications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Bayer AG
6.1.3 Eli Lilly and Company
6.1.4 F. Hoffmann-La Roche
6.1.5 Hisamitsu Pharmaceutical Co. Inc.
6.1.6 Merck KGaA
6.1.7 Mylan NV
6.1.8 Novartis AG
6.1.9 Novo Nordisk AS
6.1.10 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Abbott Laboratories
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Hisamitsu Pharmaceutical Co. Inc.
  • Merck KGaA
  • Mylan NV
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll